Follows women with sickle cell disease and their babies after hydroxyurea exposure
Records the effects of hydroxyurea on women with sickle cell disease and their babies.
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Registry title
- Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 22 Dec 2019
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 2 groups
- Treatments tested
- Chart Review
- Survey
- Record updated
- 18 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with sickle cell disease who were pregnant and took hydroxyurea during pregnancy or breastfeeding, and for their babies. It uses past medical records.
- Sex
- All sexes are listed in the record; the trial looks at women with sickle cell disease and their babies.
- Disease stage
- Sickle cell disease
- Earlier treatment
- Hydroxyurea exposure during pregnancy and/or while breastfeeding.
Main reasons for not taking part
- Medical records are not available
- No information about hydroxyurea exposure
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Medical records or data available from previous clinical care prior to June 20, 2019 of pregnant females with SCD, including women who miscarried, had a still birth, or completed labor at any gestational stage, with any hydroxyurea exposure during either pregnancy and/or while breastfeeding
- Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women
Who cannot take part
- Unavailable medical records or lack of information about hydroxyurea exposure
Where in United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Teresa LathamTaking people
About the trial
What the trial wants to find out
The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.
The 2 groups in the trial
- Retrospective Chart Review
Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
Treatment: Chart Review
- Participant Survey and Retrospective Chart Review
Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
Treatment: Chart Review and Survey
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
- Plain-language title
- Follows women with sickle cell disease and their babies after hydroxyurea exposureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 June 2026